RebiQoL: A randomized trial of telemedicine patient support program for health-related quality of life and adherence in people with MS treated with Rebif
Source: Landtblom et al. 2019 - Pubmed ID: 31276502
Setting: Sweden, Multicenter and 11 Multiple Sclerosis Centers
Study design:
RCT
Follow-up: 12 months
Patient group:
Sample size:
Total: 93(77)
IG: 46(38)
CG: 47(39)
Inclusion criteria:
- Relapsing Remitting Multiple Sclerosis
- Treated with Rebif (22 or 44 mcg 3x/week)
- Rebismart
Type of technology:
Phone Calls
- Health coaching
- Disease management
- Technical support
E-mails
- In-depth information
SMS
- Reminders
Webpage
- Health journal
Intervention:
Intervention: Patient support program offered by independent vendor.
Duration: 12 months
Add on: +
Control group: Usual Care with technical support
Clinical effect:
- MS Impact Scale-psychological →
- MS Impact Scale-full scale →
- EQ5D-5L →
- Fatigue Severity Scale →
- Modified Fatigue Impact Scale →
- HADS →
- Adherence to treatment →
Patient safety:
- No deaths
Patient experiences/
Staff experiences:
Patient experiences: NA
Staff experiences: NA
Investment: NA
Running:
Staff Resources
- Health Coaching (by independent vendor)
Organization: NA
Health care utilization: NA